On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that symptoms of differentiation syndrome, a life-threatening side effect of ···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 164
Ivosidenib Indications1. LeukemiaIvosidenib, used in combination with azacitidine or as monotherapy, is indicated for newly diagnosed acute myeloid le···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 161
In addition to its expected therapeutic effects, some adverse side effects may occur during treatment with ivosidenib. While not all side effects will···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 161
Enasidenib was developed by Celgene in the United States and approved for marketing by the US FDA on August 1, 2017.Enasidenib (EnglishIndications)Ena···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 160
Enasidenib is indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have been diagnosed with an isocitrate dehydro···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 160
Avatrombopag (Doptelet) increases platelet production by mimicking the action of endogenous thrombopoietin (TPO), activating TPO receptors, and promot···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 163
Avatrombopag (Doptelet) has different dosages and precautions for patients with chronic liver disease and chronic immune thrombocytopenic purpura. It ···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 160
Avatrombopag (Doptelet) is an oral small-molecule thrombopoietin receptor agonist (TPO-RA) that effectively increases preoperative platelet levels in ···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 162
When taking avatrombopag (Doptelet), serious side effects such as bleeding gums and nosebleeds, and abnormal weight gain or loss may occur; milder sid···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 158
On May 21, 2018, the U.S. Food and Drug Administration (FDA) approved avatrombopag (Doptelet) tablets for the treatment of thrombocytopenia (low plate···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 155
On June 27, 2019, the U.S. Food and Drug Administration (FDA) approved the expansion of the indication for avatrombopag (Doptelet) to include the trea···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 165
On July 25, 2025, the U.S. Food and Drug Administration (FDA) approved avatrombopag (Doptelet) for the treatment of thrombocytopenia in pediatric pati···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 179
Entrectinib is a targeted anticancer drug primarily used to treat solid tumors and lymphomas carrying specific gene mutations. Common side effects inc···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 168
Entrectinib is a targeted anticancer drug primarily used to treat solid tumors and lymphomas carrying specific gene mutations. Common side effects inc···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 166
The price of entrectinib fluctuates depending on the strength, purchase channel, and region. The original brand-name drug may be more expensive, while···【Read More】
Update: 2026-03-09Source: Haiou HealthViews: 158
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos